Racura Oncology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Racura Oncology and similar public comparables like Oryzon Genomics, Lineage Cell Therapeutics, Medipost, Ourofino and more.

Racura Oncology Overview

About Racura Oncology

Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.


Founded

2011

HQ

Australia

Employees

N/A

Financials (FY)

Revenue: -
EBITDA: ($5M)

EV

$261M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Racura Oncology Financials

Racura Oncology reported last fiscal year revenue of - and negative EBITDA of ($5M).

In the same fiscal year, Racura Oncology generated ($5M) in EBITDA losses and had net loss of ($5M).

Revenue (LTM)


Racura Oncology P&L

In the most recent fiscal year, Racura Oncology reported revenue of - and EBITDA of ($5M).

Racura Oncology is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Racura Oncology
Last FY202320242025202620272028
Revenue--$3M$2M
EBITDA($5M)($11M)($10M)($6M)
EBITDA Margin--(299%)(361%)
EBIT Margin--(305%)(373%)
Net Profit($5M)($8M)($7M)($4M)
Net Margin--(193%)(246%)

Financial data powered by Morningstar, Inc.

Racura Oncology Stock Performance

Racura Oncology has current market cap of $276M, and enterprise value of $261M.

Market Cap Evolution


Racura Oncology's stock price is $1.41.

Racura Oncology share price increased by 3.7% in the last 30 days, and by 71.1% in the last year.

Racura Oncology has an EPS (earnings per share) of $-0.03.

See more trading valuation data for Racura Oncology
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$261M$276M-0.2%3.7%-19.4%71.1%$-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Racura Oncology Valuation Multiples

Racura Oncology trades at (53.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Racura Oncology

EV / Revenue (LTM)


Racura Oncology Financial Valuation Multiples

As of August 10, 2026, Racura Oncology has market cap of $276M and EV of $261M.

Racura Oncology has a P/E ratio of (55.3x).

Last FY202320242025202620272028
EV/Revenue--76.7x153.3x
EV/EBITDA(53.9x)(23.3x)(25.6x)(42.5x)
EV/EBIT(51.6x)(22.9x)(25.1x)(41.1x)
P/E(55.3x)(32.9x)(42.0x)(66.0x)
EV/FCF(54.8x)(36.7x)(52.4x)(65.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Racura Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Racura Oncology Margins & Growth Rates

Racura Oncology grew EBITDA by 187% in the last fiscal year.

See estimated margins and future growth rates for Racura Oncology

Racura Oncology Margins

20242025202720282029
EBITDA Margin(299%)(361%)
EBIT Margin(305%)(373%)
Net Margin(193%)(246%)
FCF Margin(146%)(235%)

Racura Oncology Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth--(50%)(100%)
EBITDA Growth187%(9%)(40%)52%
EBIT Growth179%(9%)(39%)51%
Net Profit Growth181%(22%)(36%)127%
FCF Growth189%(30%)(20%)132%

Data powered by FactSet, Inc. and Morningstar, Inc.

Racura Oncology Operational KPIs

Access forward-looking KPIs for Racura Oncology
20242025202620272028
S&M Expenses to Revenue7%10%
G&A Expenses to Revenue51%95%
R&D Expenses to Revenue208%271%
Opex to Revenue305%449%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Racura Oncology Competitors

Racura Oncology competitors include Oryzon Genomics, Lineage Cell Therapeutics, Medipost, Ourofino, Adagene, Cellectis, Whitehawk Therapeutics, InflaRx, Shanghai Hile Bio-Tech and Veraxa Biotech.

Most Racura Oncology public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Oryzon Genomics-52.6x(47.3x)(31.4x)
Lineage Cell Therapeutics15.8x22.0x(10.9x)(6.7x)
Medipost4.4x-(4.1x)-
Ourofino1.3x-5.3x-
Adagene26.5x14.6x(12.1x)(7.8x)
Cellectis2.5x2.9x(5.8x)(3.3x)
Whitehawk Therapeutics17.6x44.9x(6.1x)-
InflaRx2633.3x40964.8x(1.7x)(1.9x)

This data is available for Pro users. Sign up to see all Racura Oncology competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Racura Oncology

When was Racura Oncology founded?Racura Oncology was founded in 2011.
Where is Racura Oncology headquartered?Racura Oncology is headquartered in Australia.
Is Racura Oncology publicly listed?Yes, Racura Oncology is a public company listed on Australian Securities Exchange.
What is the stock symbol of Racura Oncology?Racura Oncology trades under RAC ticker.
When did Racura Oncology go public?Racura Oncology went public in 2016.
Who are competitors of Racura Oncology?Racura Oncology main competitors include Oryzon Genomics, Lineage Cell Therapeutics, Medipost, Ourofino, Adagene, Cellectis, Whitehawk Therapeutics, InflaRx, Shanghai Hile Bio-Tech, Veraxa Biotech.
What is the current market cap of Racura Oncology?Racura Oncology's current market cap is $276M.
Is Racura Oncology profitable?No, Racura Oncology is not profitable.
How many companies Racura Oncology has acquired to date?Racura Oncology hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Racura Oncology has invested to date?Racura Oncology hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Racura Oncology

Lists including Racura Oncology

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial